Revance Therapeutics’ $17 Million Investor Settlement Receives Preliminary Approval

On Tuesday, April 14, 2026, a federal judge granted preliminary approval to a $17 million settlement resolving a class-action securities lawsuit against Revance Therapeutics, Inc. (NASDAQ: RVNC). The lawsuit alleged that Revance misled investors regarding the FDA approval process for its lead drug candidate, DaxibotulinumtoxinA (DAXI) for injection. Specifically, the suit claimed the company failed to disclose critical manufacturing and quality control deficiencies that led to an FDA rejection in 2021. With this first “court nod,” the settlement moves into the notification phase for thousands of eligible shareholders.

Quick Facts for Shareholders

Field	Detail
Settlement Amount	$17,000,000
Preliminary Approval Date	April 14, 2026
Class Period	November 25, 2019 – October 11, 2021
Primary Allegation	Securities fraud related to DAXI manufacturing
Final Fairness Hearing	Anticipated late 2026

The “Root Cause” – The DAXI Manufacturing Probe

The settlement stems from a period of high volatility for Revance stock linked to the FDA’s “Form 483” and the subsequent rejection of their Biologics License Application (BLA).

• The FDA Inspection: In July 2021, the FDA inspected Revance’s Northern California facility and issued a Form 483, noting that the manufacturing process used for DAXI was not the one proposed for licensure.
• The “Misleading” Claims: Investors alleged that while Revance “touted” their approval path, they were privately aware of serious quality unit failures and a lack of authority over outsourced activities.
• The Stock Drop: When the truth was revealed in October 2021—including a Complete Response Letter (CRL) from the FDA—Revance’s stock price plummeted by nearly 40% in a single day, erasing hundreds of millions in market value.

Related article”: Ex-Kaiser Employee Denied Share of Record $556 Million Medicare Fraud Settlement

How to Claim Your Share

Now that preliminary approval has been granted, the settlement administrator will begin the formal outreach process.

1. Check Eligibility: You are likely a class member if you purchased or acquired RVNC securities between November 25, 2019, and October 11, 2021.
2. Watch for Notice: A formal “Notice of Settlement” and Proof of Claim form will be mailed to shareholders of record and available on the settlement website (to be launched shortly).
3. Submit Your Information: If you held shares through a broker like Robinhood or Fidelity, they may provide the data automatically, but you should still manually verify your claim on the portal to ensure payment.
4. Deadline: While the final deadline is not yet set, claim windows in securities cases typically stay open for 90 to 120 days after the notice is mailed.

Frequently Asked Questions

Does this settlement mean Revance admitted to fraud?

No. As is standard in securities litigation, Revance denies all allegations of wrongdoing and is settling to avoid the expense and uncertainty of a prolonged trial.

What happened to DAXI after the lawsuit?

Despite the initial setback, DAXI (marketed as Daxxify) eventually received FDA approval in September 2022. However, this settlement specifically compensates investors for the losses incurred during the period of the alleged 2021 concealment.

Is there a second lawsuit?

Yes. Investors should note there is a separate, newer class action involving a class period in 2024 regarding a distribution dispute with Teoxane SA. This $17M settlement does not cover that later case.

“Missing Pillars” of Legal Reporting

• Discovery Insights: Thousands of internal emails and FDA correspondence records were reviewed. Plaintiffs’ counsel argued these showed that Revance executives were warned by their own Quality Unit about the BLA risks months before disclosing them to the public.
• Bellwether Context: This case is a “bellwether” for Biotech BLA Disclosure. It clarifies that simply “anticipating approval” is not a safe harbor for a company if they are in possession of a negative FDA Form 483 that has not been shared with the market.
• Objector Status: At this stage, no major institutional investors have objected to the $17M figure, which represents a significant recovery for a mid-cap biotech firm.
• Tax Implications: Settlements for “Capital Loss” are generally considered a return of capital. This means the payout usually reduces your “cost basis” in the stock rather than being taxed as ordinary income, unless the payout exceeds your original investment.
• Attorney Fee Breakdown: The court has preliminarily allowed for up to $5.6 million (33%) in attorney fees and expenses to be deducted from the $17 million fund.

Last Updated: April 14, 2026

Disclaimer: This article is for informational purposes only and does not constitute legal advice. For advice regarding a particular situation, consult a qualified attorney.